Italia markets closed

180 Life Sciences Corp. (ATNF)

NasdaqCM - NasdaqCM Prezzo in tempo reale. Valuta in USD.
Aggiungi a portafoglio
5,41+0,95 (+21,30%)
Alla chiusura: 1:00PM EST
5,75 +0,34 (+6,28%)
Dopo ore: 04:58PM EST
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente4,46
Aperto4,46
Denaro5,56 x 1400
Lettera5,55 x 1200
Min-Max giorno4,27 - 5,56
Intervallo di 52 settimane2,18 - 13,05
Volume2.288.024
Media Volume803.433
Capitalizzazione184,029M
Beta (5 anni mensile)-0,23
Rapporto PE (ttm)N/D
EPS (ttm)-1,07
Prossima data utiliN/D
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1A11,00
  • GlobeNewswire

    180 Life Sciences Corp. Expands Patent Portfolio

    New IP Relates to a Method for Treating Chronic Pain or Associated Conditions/Symptoms with Novel Compositions Including Certain Phenyl Substituted Cyclohexenyl Compounds Related to Cannabidiol (CBD)PALO ALTO, Calif., Nov. 22, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced th

  • GlobeNewswire

    180 Life Sciences Corp. Co-Founder Prof. Jagdeep Nanchahal to Present a Keynote Address at the 2021 International Dupuytren Symposium

    ‘Re-purposing anti-TNF for Dupuytren’s Disease’ Being Presented Wednesday, December 1, 2021, at 3pm ESTPALO ALTO, Calif., Nov. 18, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced that Professor Jagdeep Nanchahal from the University of Oxford, a co-founder of 180 Life Sciences,

  • GlobeNewswire

    180 Life Sciences Corp. Names Quan A. Vu Chief Operating Officer/Chief Business Officer

    Highly Accomplished Strategy, Corporate/Business Development, Finance and Operations Executive With 20 Years of Biopharma ExperiencePALO ALTO, Calif., Nov. 03, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced the appointment of Quan A. Vu to the role of Chief Operating Officer/